Female using Rogaine foam for hair loss had scalp punch biopsy, diagnosed with Androgenetic Alopecia (AGA). Doctor recommended starting Spironolactone 50mg.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.
KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.
A 26 year old female diagnosed with androgenetic alopecia who is interested in treatments such as spironolactone, finasteride and Minoxidil to help her hair loss but is worried about side effects like muscle gain, sex drive and effectiveness.
Sodium Laureth Sulfate (SLS) in shampoos and its potential impact on thinning hair. The user follows a regimen of shampoo, keto shampoo, and conditioner, seeking suggestions for better products.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.
The user has been using minoxidil foam and mesotherapy with dutasteride since February 2024 for hair loss. They are seeking opinions on their progress, considering dermarolling, and asking for shampoo suggestions.
A 20-year-old male experienced significant hair shedding for nearly 10 months, despite using finasteride, oral minoxidil, and ketoconazole, and is concerned about chronic telogen effluvium. He has been supplementing with vitamins and minerals but remains unsure of the cause.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
Breezula may be released around 2027 but its effectiveness for advanced thinning is uncertain, and it might be expensive. Users discuss alternatives like low-dose topical finasteride and combining it with Breezula for better results.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
A user's scalp issue that may be causing their hair loss and potential treatments, such as salicylic acid, finasteride, minoxidil, ketoconazole shampoo, and visiting a dermatologist.
PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.
The conversation discusses using Morr F Aqua, an alcohol-free version of Minoxidil, for hair loss, particularly for someone with dandruff issues. The user is considering if this product is suitable for their condition.
The user has been using finasteride for 6 months with decent results and recently added topical minoxidil. They are concerned that salicylic acid in their skincare products might reduce minoxidil's effectiveness.
The user has been using finasteride for 8 years and started using minoxidil foam 5% twice daily with micro-needling since May 2025. They experienced significant shedding starting in July and are seeking information on how long the shedding will last and when to expect positive results.
The conversation discusses the potential of Sanguisorba Officinalis Root Extract as a treatment for hair loss by inhibiting FGF-5. The user also mentions the product évolis, which is based on this extract but is only available in the US and Australia.
Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.
Minoxidil non-responders may benefit from using minoxidil sulfate due to reduced sulfotransferase activity in their scalps. Users are encouraged to share their experiences with minoxidil sulfate.
Hypoxia may enhance hair growth by stimulating stem cells, but it could also risk fibrosis. Some users humorously discuss extreme methods like choking while using minoxidil, highlighting the need for new treatments.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.
A 28-year-old male is experiencing excessive hair shedding despite using oral and topical minoxidil, and occasionally using ketoconazole shampoo. He is considering trying GHK-Cu serums but cannot use finasteride.
The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.